65,437 trials
Obesity
Primary: Change in Weight — -4.79 kg
Nicotine Dependence
Primary: Number of Eligible Participants Enrolled Who Completed the Study. — 9; 8 Participants
Hematological Neoplasms · Hematopoietic Stem Cell Transplantation
Primary: Number of Participants Experiencing Transplant Related Mortality (TRM) — 0 Participants
Plaque Psoriasis
Primary: Percentage of Subjects Who Achieve Psoriasis Area and Severity Index (PASI) 75 at Week 16 — 22.4; 44.9 Percentage of Subjects — p=0.032
Non-Small Cell Lung Cancer
Primary: Progression-free Survival — 1.91; 3.52 months
Cystic Fibrosis
Primary: Change in CFQ-R Respiratory Symptoms Scale (RSS) Score — -2.63; 7.08 units on a scale — p=0.0005
Hepatitis C · Chronic Hepatitis C
Primary: Number of Participants With Biometrical Adherence to Therapy — 406; 415; 413 Participants
Rheumatoid Arthritis
Primary: Reliability of the European League Against Rheumatism - Rheumatism Arthritis Impact of Disease (EULAR-RAID) Score — 0.85 intraclass correlation coefficient — p=0.000
Nasolabial Folds
Primary: Procedural Pain Score — 2.0; 4.1 units on a scale
Varicella
Primary: Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process). — 96.3 Percent of participants
Chronic Lymphocytic Leukemia · Leukemia
Primary: Number of Patients in Overall Response Categories — 3; 1; 10; 30 Participants
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Multiple Myeloma
Primary: Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term) — 2.3; 1.8 RBC Transfusions — p=<0.025
Onychomycosis
Primary: Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks — 1.18; 0.96 Percentage of participants
Onychomycosis
Primary: Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks. — 0.79; 0.78; 1.47; 0.00 Percentage of Participants